Scarica l'app Stockscreener
1.54
3.75%
-0.06
Pre-mercato:
1.61
0.07
+4.55%
Precedente Chiudi:
$1.60
Aprire:
$1.62
Volume 24 ore:
510.55K
Relative Volume:
0.38
Capitalizzazione di mercato:
$92.89M
Reddito:
-
Utile/perdita netta:
$-27.37M
Rapporto P/E:
-3.3831
EPS:
-0.4552
Flusso di cassa netto:
$-25.99M
1 W Prestazione:
+1.32%
1M Prestazione:
-27.70%
6M Prestazione:
-71.27%
1 anno Prestazione:
-69.14%
Intervallo 1D:
$1.52
$1.63
Intervallo di 1 settimana:
$1.49
$1.67
Portata 52W:
$1.07
$6.175
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Nome
Aldeyra Therapeutics Inc
Settore
Industria
Telefono
781-761-4904
Indirizzo
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
1.54 | 95.61M | 0 | -27.37M | -25.99M | -0.4552 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-04-03 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-04-02 | Ripresa | H.C. Wainwright | Buy |
| 2022-04-27 | Ripresa | H.C. Wainwright | Buy |
| 2021-02-08 | Iniziato | H.C. Wainwright | Buy |
| 2020-12-16 | Iniziato | Berenberg | Buy |
| 2020-10-30 | Iniziato | Jefferies | Buy |
| 2020-10-16 | Iniziato | BTIG Research | Buy |
| 2020-09-22 | Iniziato | Alliance Global Partners | Buy |
| 2020-05-12 | Iniziato | Oppenheimer | Outperform |
| 2018-12-04 | Iniziato | Citigroup | Buy |
| 2018-09-26 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Iniziato | Janney | Buy |
| 2018-01-26 | Iniziato | Seaport Global Securities | Buy |
| 2016-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2016-07-01 | Iniziato | Stifel | Buy |
| 2015-07-01 | Iniziato | Canaccord Genuity | Buy |
| 2015-03-25 | Iniziato | Chardan Capital Markets | Buy |
| 2015-03-20 | Reiterato | H.C. Wainwright | Buy |
| 2014-11-18 | Iniziato | H.C. Wainwright | Buy |
| 2014-06-19 | Iniziato | Aegis Capital | Buy |
Mostra tutto
Aldeyra Therapeutics Inc Borsa (ALDX) Ultime notizie
Aldeyra Therapeutics Inc (ALDX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BlackRock (ALDX holder) discloses 1.7% Aldeyra Therapeutics stake in amended 13G - Stock Titan
Aldeyra Therapeutics Inc (ALDX) Institutional Confidence - TradingKey
Aldeyra Therapeutics Inc (ALDX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Aldeyra Therapeutics Inc (ALDX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aldeyra Therapeutics Inc (ALDX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aldeyra Therapeutics Inc (ALDX) Cash Flow - TradingKey
Aldeyra Therapeutics, Inc. Revenue Breakdown – NASDAQ:ALDX - TradingView
ALDX|Aldeyra Therapeutics Inc|Price:1.580|Chg%:+0.060 - TradingKey
Aldeyra Therapeutics Inc (ALDX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aldeyra Therapeutics Inc (ALDX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ALDX|Aldeyra Therapeutics Inc|Price:1.520|Chg%:-0.030 - TradingKey
Aldeyra Therapeutics Inc (ALDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ALDX Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Aldeyra Therapeutics Inc (ALDX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Reach Out - ACCESS Newswire
Price to sales forward of Aldeyra Therapeutics, Inc. – FWB:137 - TradingView
Revenue per share of Aldeyra Therapeutics, Inc. – FWB:137 - TradingView
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Reach Out - ACCESS Newswire
2026-07-19 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Reach Out | NDAQ:ALDX | Press Release - Stockhouse
Aldeyra Therapeutics Inc. (ALDX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Aldeyra Therapeutics to seek Type D meeting with FDA on reproxalap NDA resubmission - TradingView
Aldeyra Therapeutics (NASDAQ: ALDX) advances FDA dialogue on reproxalap NDA - Stock Titan
Understanding the Setup: (ALDX) and Scalable Risk - Stock Traders Daily
ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - AOL.com
Aldeyra Therapeutics: What Comes Next After Reproxalap's Third CRL (NASDAQ:ALDX) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Connect - ACCESS Newswire
ALDX EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - AOL.com
ALDX Shareholder Alert: Aldeyra Therapeutics, Inc. Securities Class Action LawsuitInvestors Should Contact The Gross Law Firm - AOL.com
Aldeyra Therapeutics (ALDX) Posts Modest Gain Amid Biotech Sector RecoveryReversal Setup Alerts - DonanımHaber
Levicept Ltd (ALDX) Appoints Darlene Deptula-Hicks as CFO Amid P - GuruFocus
Levicept Appoints Darlene Deptula-Hicks as CFO - GlobeNewswire Inc.
Aldeyra Therapeutics Q1 2026 Earnings: Narrower Loss Beats Estimates, Pipeline Progress Remains Key - DonanımHaber
Why Did ALDX Stock Tank 70% Today? - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Reach Out - ACCESS Newswire
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Spotlight On Aldeyra Therapeutics And 2 Other Prominent Penny Stocks - Sahm
ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Aldeyra Therapeutics, Inc. Actuals & Estimates (TRADEGATE:137) - TradingView
ALDX News | ALDEYRA THERAPEUTICS INC (NASDAQ:ALDX) - ChartMill
The Technical Signals Behind (ALDX) That Institutions Follow - Stock Traders Daily
ALDX Stockholders Have Opportunity to Lead Aldeyra Therapeutics - The National Law Review
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
Aldeyra Therapeutics (ALDX) Edges Higher Near Support; Key Resistance AheadETF Outflow Streak - dars.gov.et
Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Aldeyra Therapeutics Inc Azioni (ALDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Aldeyra Therapeutics Inc Azioni (ALDX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| DOUGLAS RICHARD | Director |
Mar 19 '26 |
Buy |
1.40 |
70,000 |
98,000 |
195,000 |
| Alfieri Michael | Principal Financial Officer |
Mar 18 '26 |
Buy |
1.42 |
5,000 |
7,100 |
7,500 |
| Alfieri Michael | Principal Financial Officer |
Aug 13 '25 |
Buy |
5.30 |
2,500 |
13,250 |
2,500 |
| Machatha Stephen | Chief Development Officer |
Aug 11 '25 |
Sale |
5.15 |
22,073 |
113,713 |
221,799 |
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):